Except the expired patent is for the old anti-fibrinogen HRP ingredient, which is either in short supply or not available at all.
Gartner can't make many test kits using the scarce anti-fibrinogen HRP, and if Gartner is making DR-70 using the new replacement ingredient, the new patent does have some importance. If what you say is true, MacLellan is now mad at Gartner and could find a lawyer to sue GCDx on a contingency basis.
But I think you're wrong. I think Gartner and MacLellan are still friends. I think Gartner wants $1.5 million so he can sign a new license agreement with MacLellan before Radient goes bankrupt. Gartner would give MacLellan $200,000 and the agreement would contain a bankruptcy clause like the UNI agreement. Without the $1.5 million and without the Radient license agreement, GCDx isn't going to sell anything. In other words, everything Gartner said GCDX is going to do is followed by the unspoken implied phrase "if I get funding."
Which means GCDx is probably never going to sell the test. I don't think Gartner will ever get his $1.5 million funding because nobody who does DD on onko-sure will invest in onko-sure. It's a failed product. It's never going to generate enough revenues to pay for operational and manufacturing costs, which means it's never going to be profitable, and biotech is not about saving the world or curing cancer -- biotech is about profit.
The only people who are saying that "onko-sure is worth billions" are RXPC shareholders who want to sell their stock. If they believed that Radient had a profitable future, they'd shut up and buy more. If they really believed the stock is going to a dime or a dollar or even a penny, they would be buying at .0002.
